Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma

• Published in: PloS one 2017-10, Vol.12 (10), p.e0186567-e0186567
• Main Authors: Lin, Chun-Yu, Wu, Yen-Mu, Hsieh, Meng-Heng, Wang, Chih-Wei, Wu, Ching-Yang, Chen, Ying-Jen, Fang, Yueh-Fu
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Aged; Biology and Life Sciences; Cancer; Cancer therapies; Classification; Development and progression; Epidermal growth factor; Epidermal growth factor receptors; Female; Gene mutations; Genetic aspects; Geriatrics; Hospitals; Humans; Kinases; Lung cancer; Lung diseases; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Medical prognosis; Medicine; Medicine and Health Sciences; Middle Aged; Multivariate analysis; Mutation; Patients; Physiological aspects; Prognosis; Quality; Receptor, Epidermal Growth Factor - genetics; Risk factors; Surgery; Survival; Thorax; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0186567

The prognostic value of epidermal growth factor receptor (EGFR) mutations and the correlation between EGFR mutations and the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) histological classification remain controversial. The current study aimed to investigate the pure prognostic role of EGFR mutations in treatment-naïve patients with resected stage I lung adenocarcinoma. We retrospectively reviewed 373 patients with stage I pulmonary non-small-cell lung cancer who underwent complete surgical resection between January 2010 and May 2014. The tumors were classified according to IASLC/ATS/ERS criteria. EGFR mutation status was determined by established methods. A total of 120 patients were included for analysis; 87 had tumors with EGFR mutations and 33 had wild-type tumors. More low- and intermediate-grade tumors had EGFR mutations, and nearly half of the high-grade tumors were wild-type (75.7% versus 46.2%, p = 0.041). Patients with low-grade tumors had significantly greater median disease-free survival (DFS) (76.8 versus 13 months, p < 0.0001) and better overall survival (OS) (median OS not reached, p = 0.0003) than those with intermediate- and high-grade tumors. Tumor recurrence was 41.4% and 30.3% in mutant and wild-type patients. The 5-years survival rate was 54% and 71.2%. Multivariate analysis revealed that the new histological classification and the pathologic stage were independent predictors of both DFS and OS. EGFR mutation status had no prognostic implications. Low grade tumors according to IASLC/ATS/ERS histological classification and the pathologic stage IA tumors of resected stage I lung adenocarcinomas independently predict better DFS and OS. EGFR mutations were frequently seen in histologically low- and intermediate-grade tumors but not a prognostic factor.